GlaxoSmithKline plc. today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib, its MEK inhibitor as adjuvant therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback